Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.